Increased awareness and early diagnosis of ATTR-CM is crucial in helping to prolong patients lives and increase their quality of life whilst reducing the strain on healthcare services.

 

The diagnosis of ATTR-CM can be challenging, with patients on average experiencing a delay in diagnosis of 2 to 6 years from the initial onset of symptoms. This is largely due to the non-specific nature of the symptoms which can mimic other common symptoms for heart conditions, often leading to a misdiagnosis of either Heart Failure (HF) or hypertrophic cardiomyopathy. 

These issues in delays significantly impact patients outcomes, with a median survival rate of 2.5-3.6 yearsand a 50% increase in hospitalisations in the year following diagnosis compared to HF patients.